VivoSeq
Ophthalmology

Myopia

30

Pipeline Programs↗

42

Active Trials↗

20

Companies Involved↗

Myopia is an emerging landscape with 30 programs across 20 companies. The most active players are Santen Pharmaceutical Co., Ltd., Sunhawk Vision Biotech, Inc., Oupushifang Pharmaceutical Technology Co., Ltd.. 9 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

43/100

Mech. Concentration

29/100

Completion Rate

77/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Santen Pharmaceutical Co., Ltd.

1 program

Phase 2S

Sunhawk Vision Biotech, Inc.

1 program

Phase 2O

Oupushifang Pharmaceutical Technology Co., Ltd.

1 program

Phase 3Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.

1 program

Phase 3Roche logo

Roche

1 program

Phase 3C

Cloudbreak Therapeutics, LLC

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical7

Bromfenac

Bausch Health Americas, Inc.

Aflibercept

Regeneron

Ofloxacin

Wim Janssens

Low Dose Atropine

The Hong Kong Polytechnic University

Artificial Tear

BRIM Biotechnology Inc.

Phase 11

Cyclopentolate

KK Women's and Children's Hospital

Phase 24

Riboflavin

Cornea and Laser Eye Institute

Investigational Bifidobacterium Preparation MR-61

Second Affiliated Hospital of Nanchang University

SHJ002

Sunhawk Vision Biotech, Inc.

IVMED 85

iVeena Delivery Systems, Inc.

Phase 39

Bevacizumab

Bio-Thera Solutions

Ranibizumab

Roche

Photodynamic Therapy

Roswell Park Cancer Institute

Atropine Sulfate

Cloudbreak Therapeutics, LLC

Placebo Eyedrops

Jaeb Center for Health Research

Approved9

Brimonidine

Novartis

Atropine

Fresenius Kabi Oncology Ltd.

Mitomycin

UroGen Pharma Ltd.

Pilocarpine

Advanz Pharma

Carboxymethylcellulose

AbbVie

Analysis

Modality Breakdown

94%

Small molecule

49 of 52 classified programs — the dominant modality here.

6%ALL OTHERSMonoclonal antibody24%Protein / enzyme12%

Small molecule leads; the ring shows all 52 classified programs, each share of the total. Modality classified for 90% of 59 pipeline programs.

Analysis

Trial Status

90

clinical trials

Completed23 · 26%
Recruiting18 · 20%
Unknown status18 · 20%
Active, not recruiting15 · 17%
Not yet recruiting9 · 10%
Withdrawn3 · 3%
Other4 · 4%

Clinical Trials

Trial Activity

90 trials

Stellest Lenses and Low-concentration Atropine Myopia Control Among Children
Recruiting·EEssilor-Polylite Taiwan Co., Ltd.·N/A·NCT06344429·100 enrolled
Orthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control
Recruiting·ZZhongshan Ophthalmic Center, Sun Yat-sen University·N/A·NCT06667037·194 enrolled
Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia
Recruiting·SSecond Affiliated Hospital of Nanchang University·Phase 2·NCT07298824·164 enrolled
The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression
Recruiting·OOupushifang Pharmaceutical Technology Co., Ltd.·Phase 3·NCT06708156·606 enrolled
Myopia Control: a Comparison Study Between Atropine and MiSight
Recruiting·—·Phase 2·NCT05815784·348 enrolled
Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)
Recruiting·OOcus Innovation Ireland Limited·Phase 3·NCT07028827·234 enrolled
MAD Trial: Myopia Atropine Dose
Recruiting·EErasmus Medical Center·Phase 3·NCT05667454·550 enrolled
Pharmacological and Non-pharmacological Treatment Effects on Children With Different Predicted Myopia Progression Rate
Recruiting·TThe Hong Kong Polytechnic University·N/A·NCT06282848·80 enrolled
Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elongation in Children.
Recruiting·LLaboratorios Sophia S.A de C.V.·Phase 3·NCT06389110·123 enrolled
Early-Onset Myopia Intervention Project
Recruiting·SShanghai Eye Disease Prevention and Treatment Center·N/A·NCT07176949·508 enrolled
A Phase 3 Clinical Study of QLM3004 in Delaying Myopia in Children
Recruiting·Qilu Pharmaceutical Co., Ltd. logoQilu Pharmaceutical Co., Ltd.·Phase 3·NCT06151587·735 enrolled
Atropine in the Treatment of Myopia Study in Malaysia
Recruiting·IIDB VisionCare SDN BHD·Phase 3·NCT07329777·144 enrolled
Atropine (0.02%, 0.04%) Combined With Defocus DIMS for Moderate and High Myopia Control
Recruiting·—·Phase 1/2·NCT06523504·410 enrolled
Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial
Recruiting·OOhio State University·Phase 3·NCT07567040·664 enrolled
Effect of Centration Compensation on Visual Quality in VisuMax 800 SMILE for Small Kappa Angles: A Randomized Trial
Recruiting·ZZhongshan Ophthalmic Center, Sun Yat-sen University·Preclinical·NCT07512115·224 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)